Amber Bolden

Amber Bolden is an associate in Goodwin’s Life Sciences group. She represents public and private life sciences and technology companies in a broad range of transactions throughout the corporate lifecycle, including startup and formation, venture capital financings, mergers & acquisitions, as well as in strategic licensing and collaborations. Amber joined Goodwin in 2026.

Amber is a member of the New York State Bar Association and the American Intellectual Property Law Association.

Prior to joining Goodwin, Amber was a Corporate Advisory associate at McDermott Will & Schulte. She was also a summer associate at McDermott Will & Schulte and Desmarais LLP.

While attending law school, Amber served as the Executive Managing Editor for the Notre Dame Journal on Emerging Technologies and as the President Emeritus of the Intellectual Property Law Society. She volunteered with the Notre Dame Exoneration Justice Clinic and, through the Notre Dame Mediation Clinic, became a licensed mediator, assisting with civil disputes in the Michiana region. Amber was also a judicial intern for the Honorable Eric Vitaliano in the United States District Court for the Eastern District of New York.

Prior to law school, Amber was an IP paralegal at Kirkland & Ellis for the pharmaceuticals team.

Amber is the author of “From Biased Data Inputs To Your Discriminatory Diagnosis Outputs: A Review of Legal Liability For Artificial Intelligence in Healthcare,” which was selected as one of two publications for the 2023 Michigan Technology Law Review inaugural notes competition (published Spring 2024).